Recent News

• 02.12.2025 - Rosnilimab Top-Line Phase 2b Rheumatoid Arthritis (RA) Data
• 02.12.2025 - Rosnilimab Top-Line Phase 2b Rheumatoid Arthritis (RA) Data
• 02.11.2025 - Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
• 02.11.2025 - Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
• 02.11.2025 - Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
• 02.07.2025 - Andy Chen
• 02.07.2025 - Andy Chen
• 02.07.2025 - Andy Chen
• 02.07.2025 - Andy Chen
• 02.05.2025 - Guggenheim SMID Cap Biotech Conference

Recent Filings

• 02.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors